Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients

International Journal of Cardiology

Volumn 155, Issue 2, 2012, Pages 236-242

  Geng, Deng Feng ^a   Jin, Dong Mei ^a   Wu, Wei ^a   Xu, Yun ^a   Wang, Jing Feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin receptor blockers; Diabetes, type 2; Hypertension; Impaired glucose tolerance; Randomized controlled trial

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; LOSARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857039149     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.011     Document Type: Article

References (34)

1. M.I. Harris Diabetes in America: epidemiology and scope of the problem Diab Care 21 1998 C11 C14
2. C.C. Cowie, K.F. Rust, and E.S. Ford Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 Diab Care 32 2009 287 294
3. T.W. Gress, F.J. Nieto, E. Shahar, M.R. Wofford, and F.L. Brancati Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study N Engl J Med 342 2000 905 912
4. A.J. Scheen Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1: a meta-analysis of randomised clinical trials Diabetes Metab 30 2004 487 496
5. H. Abuissa, P.G. Jones, S.P. Marso, and J.H. O'Keefe Angiotensin- converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials J Am Coll Cardiol 46 2005 821 826
6. E.L. Gillespie, C.M. White, M. Kardas, M. Lindberg, and C.I. Coleman The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes Diab Care 28 2005 2261 2266
7. K.A. Jandeleit-Dahm, C. Tikellis, C.M. Reid, C.I. Johnston, and M.E. Cooper Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes J Hypertens 23 2005 463 473
8. T. Ogihara, K. Nakao, and T. Fukui Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 51 2008 393 398
9. H. Kasanuki, N. Hagiwara, and S. Hosoda Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) Eur Heart J 30 2009 1203 1212
10. T. Sawada, H. Yamada, B. Dahlöf, H. Matsubara, and KYOTO HEART Study Group Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur Heart J 30 20 2009 2461 2469
11. S. Yusuf, H.C. Diener, and R.L. Sacco Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 12 2008 1225 1237
12. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators S. Yusuf, and K. Teo Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 9644 2008 1174 1183
13. NAVIGATOR Study Group, J.J. McMurray, and R.R. Holman Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
14. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (May 2005).
15. H. Lithell, L. Hansson, and I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hyperten 21 2003 875 886
16. C.B. Granger, J.J. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
17. S. Yusuf, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 9386 2003 777 781
18. S. Julius, S.E. Kjeldsen, and M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
19. L.H. Lindholm, H. Ibsen, and B. Dahlöf Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010
20. S. Bangalore, S. Parkar, E. Grossman, and F.H. Messerli A meta-analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus Am J Cardiol 100 8 2007 1254 1262
21. C. Vitale, G. Mercuro, and C. Castiglioni Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome Cardiovasc Diabetol 4 2005 6
22. E.L. Kuti, W.L. Baker, and C.M. White The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker Curr Med Res Opin 23 2007 1239 1244
23. S. Julius, M.A. Weber, and S.E. Kjeldsen The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy Hypertension 48 2006 385 391
24. ONTARGET Investigators S. Yusuf, and K.K. Teo Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
25. W.J. Elliott, and P.M. Meyer Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 2007 201 207
26. J.A. Staessen, J.G. Wang, and L. Thijs Cardiovascular prevention and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
27. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
28. J.G. Wang, Y. Li, S.S. Franklin, and M. Safar Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview Hypertension 50 2007 181 188
29. G.C. Lu, J.W. Cheng, K.M. Zhu, X.J. Ma, F.M. Shen, and D.F. Su A systematic review of angiotensin receptor blockers in preventing stroke Stroke 40 2009 3876 3878
30. S.E. Kjeldsen, G.T. McInnes, and G. Mancia Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial Blood Press 17 2008 170 177
31. T.A. Aksnes, S.E. Kjeldsen, M. Rostrup, P. Omvik, T.A. Hua, and S. Julius Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population Hypertension 50 2007 467 473
32. L.H. Lindholm, M. Persson, P. Alaupovic, B. Carlberg, A. Svensson, and O. Samuelsson Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) J Hypertens 21 2003 1563 1574
33. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
34. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150